FIELD: pharmacology.
SUBSTANCE: this invention relates to a composition comprising an esterified anti-inflammatory lipoid mediator which is an anti-inflammatory lipid mediator ether that is the product of the reaction of an anti-inflammatory lipid mediator and a monohydric alcohol or amide, with most of the anti-inflammatory lipoid mediator present in the form of an ester. Thus, the compositions contain 10 wt % or less of the acid form of the anti-inflammatory lipoid mediator. Anti-inflammatory lipid mediators may be selected from the group consisting of polyunsaturated fatty acids (for example, omega-3 and omega-6 fatty acids), resolvins or a metabolically stable analogue, proteins or metabolically stable analog, lipoxins or a metabolically stable analog, prostaglandins or a metabolically stable analogue, retinoic acid, endocannabinoids, their metabolites and mixtures.
EFFECT: composition can be delivered locally to the eye surface with an impregnated or hydrated contact lens.
30 cl
| Title | Year | Author | Number |
|---|---|---|---|
| ESTERS FOR TREATMENT OF OPHTHALMOLOGICAL INFLAMMATORY DISEASES | 2012 |
|
RU2640506C9 |
| ESTERS FOR TREATMENT OF OPHTHALMIC INFLAMMATORY DISEASES | 2012 |
|
RU2747953C2 |
| COMPOUND ETHERS FOR TREATMENT OF OPHTHALMOLOGICAL INFLAMMATORY DISEASES | 2012 |
|
RU2673230C1 |
| ESTERS FOR TREATING OPHTHALMIC INFLAMMATORY DISEASES | 2012 |
|
RU2707961C2 |
| COMPOSITIONS AND METHODS FOR EYE TREATMENT | 2019 |
|
RU2793736C2 |
| COMPOSITIONS AND METHODS OF TREATING EYE DISORDERS | 2019 |
|
RU2802365C2 |
| STABILIZED OPHTHALMIC COMPOSITIONS CONTAINING OMEGA-3-ACIDS | 2015 |
|
RU2697844C2 |
| COMPOSITIONS AND METHODS FOR TREATING EYE DISORDERS | 2019 |
|
RU2792627C2 |
| PHARMACEUTICAL FORMULATIONS OF NON-POLAR AND POLAR LIPIDS FOR OPHTHALMOLOGICAL APPLICATION | 2007 |
|
RU2495661C2 |
| OPHTHALMOLOGICAL COMPOSITION, BASED ON POLYUNSATURATED FATTY ACIDS OMEGA-3 AND OMEGA-6 | 2010 |
|
RU2545675C2 |
